Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00042081 · ClinicalTrials.gov registry record · Phase 3
Prevention of Autogenous Vein Graft Failure in Coronary Artery Bypass Procedures
A Phase 3 study, sponsored by Anesiva.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,000
- Enrollment target
NCT00042081 is a Phase 3 study that has completed, run by Anesiva. The registered enrollment target is 3,000 participants.
The verdict
NCT00042081, a Phase 3 study, has completed, sponsored by Anesiva.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,000 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy of graft pretreatment with CGT003 (E2F Duplex Decoy), as compared to placebo, on the incidence of patients experiencing vein graft failure after coronary artery bypass surgery.
Interventions
- DRUG CGT003 (E2F Duplex Decoy)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2002-07 |
| Est. Completion | 2005-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00042081
The ClinicalTrials.gov registry entry for NCT00042081 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Anesiva, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CGT003 (E2F Duplex Decoy) is the first listed.
NCT00042081 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00042081 about?
NCT00042081 is a clinical study titled "Prevention of Autogenous Vein Graft Failure in Coronary Artery Bypass Procedures". The purpose of this study is to determine the efficacy of graft pretreatment with CGT003 (E2F Duplex Decoy), as compared to placebo, on the incidence of patients experiencing vein graft failure after coronary artery bypass surgery.
What is the current status of trial NCT00042081?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,000 participants. The study started on 2002-07. Estimated completion is 2005-02.
What interventions are being tested in trial NCT00042081?
The interventions under investigation include: CGT003 (E2F Duplex Decoy) (DRUG).
Who is sponsoring clinical trial NCT00042081?
This trial is sponsored by Anesiva, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.